The Food and Drug Administration (FDA) has approved Moderna’s next-generation mRNA COVID-19 vaccine mNexspike ®.

The product is a new vaccine against COVID-19, for use in all adults 65 and older, as well as individuals aged 12-64 years.

The Food and Drug Administration (FDA) has approved Moderna’s next-generation mRNA COVID-19 vaccine mNexspike ®. The new vaccine is indicated for active immunization to prevent COVID-19 caused ...

mNexspike is approved for older adults aged 65 and for individuals aged 12-64 with at least one underlying condition that puts them at high risk for severe COVID-19. Moderna had originally sought ...

The U.S. Food and Drug Administration has approved a new lower-dose vaccine for active immunization against COVID-19 caused ...

HHS Secretary Robert F. Kennedy Jr. says Moderna (MRNA) has agreed to do another clinical trial to back its newly approved ...

The Federal Circuit upheld a ruling that Moderna's COVID-19 vaccine does not infringe Alnylam's mRNA patents related to the SM-102 lipid used in Spikevax.

Sanofi announced it is punting more than $9 billion to acquire Blueprint Medicines and its Ayvakit, BLU-808 and immunology ...